Huadong hospital, Fudan University
Shanghai, Shanghai Municipality, 200040, China
NCT Number: NCT07136246
This study aims to explore the diagnosis, impact, and prognostic factors of COPD complicated with sarcopenic obesity using multi-segment bioelectrical impedance phase angle technology. It seeks to clarify the diagnostic value and efficacy of body composition analysis in specific populations, analyze the relationship between phase angle and COPD severity as well as quality of life, investigate its predictive role for adverse outcomes, and reveal the effects of inflammation and metabolic disorders in sarcopenic obesity. The goal is to provide a basis for early screening and precise intervention to improve patient prognosis.
Looking for future studies?
Notify Me65 year and older
All sexes
Observational
Shanghai, Shanghai Municipality, 200040, China
The primary objective of this study is to use multi-segment bioelectrical impedance phase angle technology to explore the diagnosis, impact, and prognostic factors of COPD complicated with sarcopenic obesity. The study aims to clarify the diagnostic value and efficacy of body composition analysis in specific populations, analyze the relationship between phase angle and COPD severity as well as quality of life, investigate its predictive role for adverse outcomes, and reveal the effects of inflammation and metabolic disorders in sarcopenic obesity. The goal is to provide a basis for early screening and precise intervention to improve patient prognosis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Bioelectrical Impedance Phase Angle Technology Measured via InBody S10 at six frequencies (1kHz-1000kHz) during each follow-up
Time frame: 6, 12, and 24 months
FEV1%
Time frame: 6, 12, and 24 months
The COPD Assessment Test (CAT) is a short, validated questionnaire used to measure the impact of COPD symptoms on a patient's daily life and health status. It consists of 8 simple questions, each scored from 0 to 5, with a total range of 0-40.Higher CAT scores = Worse COPD symptoms & greater disease burden
Time frame: 6, 12, and 24 months
Segmental phase angles measured via bioelectrical impedance analysis
Time frame: 6, 12, and 24 months
The Modified Medical Research Council(mMRC) scale is a simple questionnaire used to assess the severity of breathlessness, primarily in respiratory diseases like COPD.range from 0-4 .Grading Criteria:Grade 1: Short of breath when walking fast or climbing a slight hill.Grade 2: Walk slower than peers or need to stop occasionally due to breathlessness.Grade 3: Stop to breathe after walking ~100 meters or a few minutes on level ground.Grade 4: Too breathless to leave home, or breathless while dressing/undressing.A higher mMRC grade correlates with greater dyspnea severity and more pronounced symptoms."
Time frame: 6, 12, and 24 months
An acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is defined as:An acute worsening of respiratory symptoms that results in additional therapy.
Time frame: 6, 12, and 24 months
Frequency of hospitalizations
Time frame: 24 months
Mortality based on Mal-Nutritional Status
Time frame: 6, 12, and 24 months
Serum level of WBC (ELISA)
Time frame: 6, 12, and 24 months
Serum level of C-Reactive Protein (ELISA)
Time frame: 6, 12, and 24 months
Serum level of albumin
Time frame: 6, 12, and 24 months
Serum level of Interleukin-6
Time frame: 6, 12, and 24 months
Serum level of Tumor Necrosis Factor-alpha
Fudan University
Other
Research on the Construction of a Prognostic Model for COPD Complicated With Sarcopenic Obesity Based on Bioelectrical Impedance Phase Angle Technology
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06822504
COPD, Chronic Disease
Roma, Italy
View Trial DetailsNCT06735573
Chronic Disease, Chronic Obstructive Pulmonary Diseases
Aberdeen, Scotland, United Kingdom
View Trial DetailsNCT06360432
Behavior, Motor Activity
Hong Kong
View Trial DetailsNCT04272073
Atrophy, Body Weight
Liverpool, United Kingdom
View Trial Details